当前位置:首页 >英文主页 >中英对照 > 中译版报告详情

印孚瑟斯(Infosys):2026生命科学2.0:以AI驱动突破研究报告(中译版)(64页).pdf

上传人: 1****1 编号:1162908 2026-03-23 64页 3.38MB

下载:

1、1Life Sciences Journal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge InstituteLIFE SCIENCES JOURNAL 2.0:DRIVING BREAKTHROUGHS WITH AI#BreakthroughsForLife2Life Sciences Journal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge Insti

2、tute2Life Sciences Journal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge Institute3Life Sciences Journal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge InstituteTable of contentsForeword:A compelling moment in thebusiness of brea

3、kthroughs 4Executive summary 6An AI-powered reboot for drug discovery 10The promise of better clinical trial outcomes 20Life sciences CRM:Who really owns the customer?30How to forge a resilient supply chain 38IT makes mergers pay off 47The shift closer to patients 55Contributors 623Life Sciences Jou

4、rnal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge Institute4Life Sciences Journal 2.0:Driving breakthroughs with AI External Document 2026 Infosys LimitedKnowledge InstituteLife sciences companies have always been in the business of breakthroughs.What sets this i

5、ndustry apart is the pairing of its relentless pursuit of new discovery with the deeply human mission behind it:to heal,restore,and improve lives.Researchers,scientists,and executives in life sciences organizations carry out this mission with intensity.They know their work touches individuals and fa

6、milies in profoundly personal ways.The tools and discipline required to develop,test,and formulate new therapies are established and well-honed.And the industrys emphasis on innovation has given it remarkable capacity to adopt new methods and technologies to create breakthroughs.This is what makes a

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
1. **AI驱动生命科学突破**:AI在药物发现(如首个AI设计药物rentosertib进入II期临床试验)、临床试验(提升招募效率65%,加速试验30-50%)和供应链优化中发挥关键作用,但需强数据治理和可解释AI。 2. **临床试验为投资重点**:58%高管将临床试验列为首要投资,平均支出3.71亿美元,旨在降低90%的药物失败率,通过去中心化试验和数字孪生提升效率。 3. **CRM转型与挑战**:CRM从销售工具转向全渠道 engagement 平台,但仅28%的医护人员认为现有策略满足需求,需重构客户关系管理。 4. **供应链与M&A韧性**:24%企业优先投资供应链,47%关注并购,AI可加速早期评估,但50%高管认为AI对并购影响有限。 5. **数据与治理核心**:生物银行(如UK Biobank)和联邦学习是AI基础,需解决数据偏见(如少数族裔代表性不足)和监管透明度问题。
AI如何革新药物研发? 临床试验如何提速增效? CRM如何重塑客户关系?
客服
商务合作
小程序
服务号
折叠